Loading
IARC estimates 3,499 new cancer cases and 1,068 cancer deaths in Malta in 2024; the commonest new cancers are breast, colorectum and prostate. This page is assembled automatically from OnCo's data: 3 trials with a site there, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 457 | 89.6 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Colorectum | 318 | 24.9 | Colorectal cancer |
| Prostate | 298 | 46.9 | Prostate cancer |
| Trachea, bronchus and lung | 239 | 18.2 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Bladder | 145 | 10.8 | Bladder & urothelial cancer |
| Non-Hodgkin lymphoma | 124 | 11.7 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Pancreas | 110 | 8.6 | Pancreatic ductal adenocarcinoma |
| Kidney | 100 | 9.8 | Renal cell carcinoma |
| Melanoma of skin | 85 | 9.4 | Melanoma |
| Thyroid | 81 | 10.2 | Thyroid cancer |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 184 | 13.4 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Colorectum | 128 | 8.4 | Colorectal cancer |
| Pancreas | 103 | 7.5 | Pancreatic ductal adenocarcinoma |
| Breast | 96 | 14.1 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Prostate | 54 | 6.1 | Prostate cancer |
| Stomach | 45 | 2.7 | Gastric & gastro-oesophageal junction cancer |
| Liver and intrahepatic bile ducts | 43 | 3.2 | Hepatocellular carcinoma |
| Bladder | 42 | 2.2 | Bladder & urothelial cancer |
| Non-Hodgkin lymphoma | 37 | 2.2 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Leukaemia | 37 | 2.3 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Trial | Lead sponsor | ||||
|---|---|---|---|---|---|
| Phase 3 | Active not recruiting | AstraZeneca | 106 | 2026-09-14 | |
| Phase 3 | Completed | Queen Mary University of London | 74 | 2021-10-06 | |
EORTC 22961 NCT00003026 | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 17 | 2012-07-02 |
Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Malta, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Malta is open is on the registry page, under Contacts and Locations.
OnCo holds no institution, company or person in Malta.
Malta is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.
Malta is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.